Induction of experimental asthma, pulmonary function measurements and specimen processing Syngeneic mice received intranasal (i.n.) instillations of 100 μg/nare standardized house dust mite (HDM) extract (Greer Laboratories, Lenoir, NC, U.S.) or phosphate-buffered saline (PBS), using an instillation volume of 12.5 μL/nare, 3 times per week (wk) up to completing 4 or 6 wks in total. Upon completion of 4 weeks with i.n. HDM or PBS, MSCs or vehicle was injected. Lung function data collection and specimen harvesting were performed at 72 hours (72-h cut-off) or two weeks (2-wk cut-off) after MSC or vehicle injection. The 72-h cut-off was aimed at analyzing early effects of the MSCs on established experimental asthma. Since the dynamics of MSC homing to lung tissues and their effects are unknown, and airway inflammation was not expected to have significant oscillations within a 3-day window postfinal challenge following a 4-week i.n. exposure, the data collection timing was an exploratory compromise between allowing the MSCs sufficient time to act, and examining their effects under well established inflammation. For the 2-wk cut-off post-MSC injection, i.n. instillations continued in order to test the late effects of MSCs under sustained allergen exposure and data collection was consistently performed at 3 days post-final challenge.
Lung function measurements were performed by forced oscillation technique with
FlexiVent equipment (SciReq, purchased through Electromedsys EMMS, Bordon, Hants, U.K.). For this purpose the animals underwent anesthesia, intubation through tracheostomy, peripheral vein catheterization and neuromuscular blockade, and data were collected upon challenge with methacholine (MCh) delivered to the inspiratory arm of the ventilator with an Aeroneb ultrasonic nebulizer (Electromedsys EMMS). The MCh concentrations employed were 0, 1.25, 2.5, 5 and 10 mg/mL. Twenty-five µL of each MCh solution were nebulized, corresponding to approximate delivered doses of 0, 1.56, 3.13, 6.25 and 12.5 mg/Kg body weight, respectively. Bronchoalveolar lavage (BAL) was collected in 5 mL of PBS, of which the supernatant of the first 1-mL fraction was separately stored for cytokine analysis. Blood for serum analysis was obtained from the right ventricle. The lungs were perfused with 2-mM ethylenediaminetetraacetic acid in PBS through the right ventricle, then fixed at 25 cmH2O standard pressure by tracheobronchial infusion of 10% formalin/PBS for 24 h, and sections were cut from paraffin blocks in parahilar and midsagittal orientation.
Specimen analyses and quantitative morphology
Total BAL cells were counted using a Neubauer hemacytometer and trypan blue dye exclusion. BAL cytocentrifuged preparations were fixed in 4% formaldehyde and stained with Wright-Giemsa for eosinophil differential counts, or counterstained with 4',6-diamidino-2- . PAS staining and quantitative morphology on lung sections. On PAS staining, goblet cells turn visibly PAS + upon increased mucus production. At the 72-h cut-off, the PAS + cells of the airway epithelium were decreased in numbers and had a reduced load of cytoplasmic PAS + material in the HDM/MSC group (B) compared with the HDM/Veh animals (A). On the 2-wk cut-off, the airway mucous load in the HDM/MSC group was increased along with airway inflammation (E) and was comparable to the HDM/Veh animals (D). Quantitative data on PAS + goblet cells are shown in (G). Scale bars: 100 μm in the lowmagnification, upper panels; 10 μm in the high-magnification, lower panels. *: P<0.05 versus PBS/MSC; †: P<0.05 versus HDM/Veh; §: P<0.05, 2-wk cut-off versus 72-h cut-off. 
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DISCUSSION -SUPPLEMENTAL COMMENTS Evidence of progenitor cell contribution to airway smooth muscle growth
Mechanisms suggested for airway smooth muscle growth in asthma involve the migration and differentiation of subepithelial myofibroblasts (S3, S4) , which may originate from circulating, bone marrow-derived, α-SMA-expressing progenitor cells termed fibrocytes (S5, S6) . Studies on bronchial biopsies showed increased subepithelial myofibroblasts (S3, S4) and fibrocyte localization upon allergen challenge in the bronchial mucosa of asthmatics (S5).
In murine asthma models, fibrocyte recruitment to the airways, and their differentiation to α-SMA + myofibroblasts, was demonstrated (S5, S7, S8) . Other studies strengthened the clinical evidence of fibrocyte involvement in airway remodeling (S6, S9, S10), and provided direct evidence that fibrocytes are present in the airway smooth muscle bundles in asthmatics of all severities (S6). Lately, a compartment termed non-organized airway contractile elements was described in the airway lamina propria, likely comprising evolving stages of α-SMA + cell differentiation from poorly differentiated precursors to myofibroblasts and mature smooth muscle cells (S11). Overall, the data support a role for recruited precursor cells in airway smooth muscle growth, and suggest the possibility that MSCs infused as an anti-inflammatory therapy might also bear a potential to favor unwanted remodeling.
Therapeutic MSCs in murine asthma models
Published data on MSCs for asthma therapy are scarce as they have just been recently produced from murine models only (S1, S2, S12-S16). The reports consistently show that MSCs attenuate airway inflammation and hyperresponsiveness, but a substantial amount of the data bear major limitations for their translatability to actual asthma due to the disease modeling approaches employed and the lack of any analysis of airway remodeling parameters apart from few exceptions (S2, S15). Over half of the studies referred did not test a therapeutic effect of MSCs, since the cells were administered prior to any airway antigen exposure and therefore before the induction of airway disease (S1, S12, S13, S16).
Furthermore, the animals in those studies were submitted to very short airway challenge protocols not reflecting airway remodeling as an important asthma feature, and a mouse strain suitable for this purpose (S17) was often not chosen (S1, S12, S16 
Airway hyperresponsiveness and AwCT mass
Our data suggest that the attenuation of airway responsiveness to methacholine observed at the 2-wk cut-off is a functional correlate of the decreased AwCT. This idea is consistent with prior studies where airway smooth muscle mass correlated with the different degrees of constitutive airway responsiveness observed among normal animals of several species (S18), and different rat strains (S19). In the experimental asthma setting, the change in bronchial responsiveness to cholinergic challenge correlated with the airway smooth muscle mass in the cat (S20), rat (S21) and mouse (S17), and computational models suggested that increased airway smooth muscle may be sufficient per se to produce airway hyperresponsiveness to contractile stimuli (S22-S24) . Those studies supported in all that the involvement of increased 
Mechanism of MSCs-driven regression of AwCT remodeling
It is noteworthy that AwCT mass decreased in dissociation from active airway inflammation. A dissociation between airway inflammation and AwCT remodeling had been reported in reverse terms. Allergen discontinuation (S34) , and treatments such as T-cell elimination (S35) or IL-13 blockade (S36), abolished airway inflammation but not the increased AwCT mass which, coupled with airway hyperresponsiveness, persisted unresolved. On the contrary, the MSCs drove in our experiments a decrease of AwCT in dissociation from restored airway inflammation, which suggests presently unexplained mechanisms that actively induce a regression of the increased AwCT. The rapidly increasing knowledge on mediators released by MSCs may provide some clues. For instance, MSCs constitutively express cyclooxygenase-2 and release prostaglandin E 2 (PGE 2 ) (S37).
Cytokine-enhanced production of PGE 2 is involved in inhibiting T cell activation and proliferation (S37-S40), and switching macrophages to an IL-10-producing immunomodulatory phenotype (S41-S43), as part of the various pathways already identified for MSC-driven immunomodulation. In turn, PGE 2 is able to reduce airway myocyte proliferation (S44) and thus might participate in the reversion of AwCT remodeling, yet such hypothesized involvement of PGE 2 would most likely be part of a greater complexity. Since the still scarce knowledge on MSC biology does not facilitate pinpointing other specific pathways, exploratory research will likely be needed as the first approach to understand how MSCs may reduce an overgrown structure that results from pathological tissue remodeling associated with chronic inflammation.
